A Prospective Non-interventional Study Investigating the Treatment Effect of Switching From Insulin Glargine to Ryzodeg (Insulin Degludec/Insulin Aspart) in a Real World Adult Population With Type 2 Diabetes in Japan
Phase of Trial: Phase IV
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Insulin degludec/insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms RESILIENT
- Sponsors Novo Nordisk
- 04 Dec 2019 Status changed from active, no longer recruiting to completed.
- 15 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2018 Status changed from not yet recruiting to recruiting.